［1］Siegel RL，Miller KD，Jemal A.Cancer statistics，2018［J］.CA Cancer J Clin，2018，68(1)：7-30.
［2］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132.
［3］Nipp R，Tramontano AC，Kong CY，et al.Disparities in cancer outcomes across age，sex，and race/ethnicity among patients with pancreatic cancer［J］.Cancer Med，2018，7(2)：525-535.
［4］Foster SA，Whalen DM，zen A，et al.Activation mechanism of oncogenic deletion mutations in BRAF，EGFR，and HER2［J］.Cancer Cell，2016，29(4)：477-493.
［5］Liu J，Li J，Li H，et al.A comprehensive analysis of candidate genes and pathways in pancreatic cancer［J］.Tumour Biol，2015，36(3)：1849-1857.
［6］Jonckheere N，Vasseur R，Van Seuningen I，et al.The cornerstone K-RAS mutation in pancreatic adenocarcinoma：From cell signaling network，target genes，biological processes to therapeutic targeting［J］.Crit Rev Oncol Hematol，2017，111：7-19.
［7］Wang X，Wang J，Chen F，et al.Detection of KRAS gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer：A preliminary study［J］.Exp Ther Med，2018，15(1)：527-531.
［8］Kamisawa T，Wood LD，Itoi T，et al.Pancreatic cancer［J］.Lancet，2016，388(10039)：73-85.
［9］Lee J，Snyder ER，Liu Y，et al.Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells［J］.Nat Commun，2017，8：14686.
［10］Pelosi E，Castelli G，Testa U.Pancreatic cancer：Molecular characterization，clonal evolution and cancer stem cells［J］.Biomedicines，2017，5(4)：65：E65.
［11］Hayashi H，Kohno T，Ueno H，et al.Utility of assessing the number of mutated KRAS，CDKN2A，TP53，and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer［J］.Pancreas，2017，46(3)：335-340.
［12］Xue FL.Pancreatic cancer telomerase reverse transcriptase the relationship between the expression and clinical pathological study［J］.Guide of China Medicine，2014，12(11)：4-5.［薛福龙.胰腺癌组织端粒酶逆转录酶的表达与临床病理的关系研究［J］.中国医药指南，2014，12(11)：4-5.］
［13］Bao Y，Prescott J，Yuan C，et al.Leukocyte telomere length，genetic variants at the TERT gene region，and risk of pancreatic cancer［J］.Gut，2016，66（6）：1116-1122.
［14］Du C，Tian XD，Yang YM.Epigenetic modifications and pancreatic cancer［J］.Chin J Exp Surg，2017，3：361-364.［杜冲，田孝东，杨尹默.表观遗传修饰在胰腺癌发生机制中的研究进展［J］.中华实验外科杂志，2017，3：361-364.］
［15］Nones K，Waddell N，Song S，et al.Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO，ITGA2 and MET signaling［J］.Int J Cancer，2014，135(5)：1110-1118.
［16］Sato N，Fukushima N，Hruban RH，et al.CpG island methylation profile of pancreatic intraepithelial neoplasia［J］.Mod Pathol，2008，21(3)：238-244.
［17］Rosty C，Geradts J，Sato N，et al.P16 Inactivation in pancreatic intraepithelial neoplasias(PanINs) arising in patients with chronic pancreatitis［J］.Am J Surg Patho，2003，27(12)：1495-1501.
［18］Frampton AE，Krell J，Prado MM，et al.Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies［J］.Oncotarget，2016，7(19)：28556-28569.
［19］Lai X，Wang M，McElyea SD，et al.A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer［J］.Cancer Lett，2017，393：86-93.
［20］Ebrahimi S，Hosseini M，Ghasemi F，et al.Circulating microRNAs as potential diagnostic，prognostic and therapeutic targets in pancreatic cancer［J］.Curr Pharm Des，2016，22(42)：6444-6450.
［21］Mikamori M，Yamada D，Eguchi H，et al.MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma［J］.Sci Rep，2017，7：42339.
［22］Luo G，Liu C，Guo M，et al.Potential biomarkers in lewis negative patients with pancreatic cancer［J］.Ann Surg，2017，265(4)：800-805.
［23］Zhang QD，Jin ZX，Hao DS.Research progress in correlation with tumor makers and pancreatic cancer［J］.Int J Immunol，2014，37(1)：57-60.［张泉东，金政锡，郝迪斯.肿瘤标志物与胰腺癌相关性的研究进展［J］.国际免疫学杂志，2014，37(1)：57-60.］
［24］Zhang Y，Jiang L，Song L.Meta-analysis of diagnostic value of serum carbohydrate antigen 199 in pancreatic cancer［J］.Minerva Med，2016，107(1)：62-69.
［25］Ao YX，Zhang QH，Wu SZ，et al.Clinical significance of CA19-9 /CA50 Ratio in the diagnosing and prognosis for patients with pancreatic carcinoma［J］.Journal of Basic and Clinical Oncology，2017，2(1)：42-45.［敖永曦，张启洪，伍时佐，等.CA199/CA50比值在不典型胰腺癌诊断及预后判断中的临床意义［J］.肿瘤基础与临床，2017，2(1)：42-45.］
［26］Ai LJ?TEX，Zhang YF，Bao YX.Clinical significance of combined detection of CA199，CA125，CA242 and CEA levels inpatients with pancreatic cancer［J］.Journal of Clinical Medicine in Practice，2014，18(16)：33-35.［艾力江?吐尔逊，张月芬，包永星.胰腺癌患者联合检测CA199、CEA、CA125、CA242的临床意义［J］.实用临床医药杂志，2014，18(16)：33-35.］
［27］Liang JJ，Kimchi ET，Staveley-O' Carroll KF，et al.Diagnostic and prognostic biomarkers in pancreatic carcinoma［J］.Int J Clin Exp Pathol，2009，2(1)：1-10.
［28］Balmaa M，Duran A，Gomes C，et al.Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues［J］.Int J Biol Macromol，2018，112：33-45.
［29］Kaur S，Smith LM，Patel A，et al.A combination of MUC5AC and CA19-9 improves the siagnosis of pancreatic cancer：A multicenter atudy［J］.Am J Gastroenterol，2017，112(1)：172-183.
［30］Zou F.Expression and significance of GPC-3 in pancreatic carcinoma［D］.Hunan：Hunan Normal University，2017.［邹方.GPC-3在胰腺癌组织中的表达及其意义［D］.湖南：湖南师范大学，2017.］
［31］Melo SA，Luecke LB，Kahlert C，et al.Glypican-1 identifies cancer exosomes and detects early pancreatic cancer［J］.Nature，2015，523(7559)：177-182.
［32］Wang XG，Chen F，Zhong ZX.Circulating tumor cells pancreatic cancer prognosis［J］.Chinese Journal of Experimental Surgery，2016，33(1)：262-264.［王晓光，陈飞，钟征翔.循环肿瘤细胞检测在胰腺癌患者中的研究现状及应用前景［J］.中华实验外科杂志，2016，33(1)：262-264.］
［33］Allard WJ，Matera J，Miller MC，et al.Tumor cells circulate in the peripherat blood of all major carcinomas but not in healthy subjects or patients with nonmalignant disease［J］.Clin Cancer Res，2004，10(2)：6897-6904.
［34］Nagrath S，Sequist LV，Maheswaran S，et al.Isolation of rare circularing tumor cells in cancer patients by microchip technology［J］.Nature，2007，450(3)：1235-1239.
［35］Karihara T，Itoi T，Sofuni A，et al.Detection of circulating tumor ceHs in patients with pancreatic cancerla preliminary result［J］.J Hepatobilary Pancreat Surg，2008，15(8)：189-195.
［36］Abbmzzese JL.New applications of gemcitabine and future directions in the management of pancreatic cancer［J］.Cancer，2002，95(4)：941-945.
［37］Quante M，Tu SP，Tomita H，et al.Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth［J］.Cancer Cell，2011，19(2)：257-272.
［38］Liao Y，Yang N，He R，et al.Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection：A new predictor for prognosis［J］.J Cancer Res Clin Oncol，2013，139(9)：1523-1528.
［39］Chen J，Wu W，Zhen C，et al.Expression and clinical significance of complement C3，complement C4b1 and apolipoprotein E in pancreatic cancer［J］.Oncol Lett，2013，6(1)：43-48.
［40］Nishii Y，Yamaguchi M，Kimura Y，et al.A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells［J］.Int J Oncol，2015，46(4)：1781-1787.
［41］Liu X，Zheng W，Wang W，et al.A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline［J］.Br J Cancer，2017，117(12)：1846-1854.
［42］Rybarczyk P，Vanlaeys A，Brassart B，et al.The transient receptor potential melastatin 7 channel regulates pancreatic cancer cell invasion through the Hsp90α/uPA/MMP2 pathway［J］.Neoplasia，2017，19(4)：288-300.
［43］Jin H，Zhao Y，Zhang S，et al.Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition［J］.Mol Med Rep，2018，17(5)：7274-7280.
［44］Koikawa K，Ohuchida K，Ando Y，et al.Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma［J］.Cancer Lett，2018，425：65-77.
［45］Grünwald B，Vandooren J，Gerg M，et al.Systemic ablation of MMP-9 triggers invasive growth and metastasis of pancreatic cancer via deregulation of IL6 expression in the bone marrow［J］.Mol Cancer Res，2016，14(11)：1147-1158.
［46］Wang NF，Tang ZG，Chen J，et al.MMP-26 mRNA and protein expression in pancreatic cancer and its clinical significance［J］.Acta Universitatis Medicinalis Anhui，2014，49(7)：981-983.［吴年付，汤志刚，陈炯，等.胰腺癌中MMP-26 mRNA和蛋白的表达及其临床意义［J］.安徽医科大学学报，2014，49(7)：981-983.］
［47］Maeda S，Kuboki S，Nojima H，et al.Duffy antigen receptor for chemokines(DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma［J］.Cytokine，2017，95：12-21.
［48］Grassi E，Durante S，Astolfi A，et al.Mutational burden of resectable pancreatic cancer，as determined by whole transcriptome and whole exome sequencing，predicts a poor prognosis［J］.Int J Oncol，2018，52(6)：1972-1980.
［49］Meng FB.Study on the expression and potential function of CXC Chemokine CXCL 16 and its receptor CXCR6 in human pancreatic cancer［D］.Liaoning：China Medical University，2014.［孟凡斌.CXC趋化因子CXCLl6及受体CXCR6在胰腺癌中的表达及作用机制研究［D］.辽宁：中国医科大学，2014.］
［50］Guo XZ，Zhang YG.Attention for problems related with the early detection of pancreatic cancer［J］.Chinese Journal of Digestion，2017，37(1)：2-4.［郭晓钟，张永国.胰腺癌早期诊断值得关注的问题［J］.中华消化杂志，2017，37(1)：2-4.］